Table 3.
Different disease and duration of response
| Pathological diagnosis | Target therapy protocol | Patients number (N) | Best responsea | Median (average) DR (months) |
|---|---|---|---|---|
| Osteosarcoma | Apatinib alone | 22 | PR | 3.1 (3.7) |
| Ewing sarcoma | Apatinib + everolimus & apatinib alone | 10 | PR | 1.5 (3.3) |
| Synovial sarcoma | Apatinib alone | 6 | PR | 5.2 (5.8) |
| MPNSTc | Apatinib alone | 3 | PR | 8.8 (10.1) |
| Epithelioid sarcoma | Apatinib + GTb | 2 | PR | (4.7) |
| UPSd | Apatinib alone | 4 | PR | 5.6 (5.0) |
| Fibrosarcoma | Apatinib alone | 1 | PR | 2.7 |
| Chondrosarcoma | Apatinib alone | 3 | PR | (7.4) |
| ASPSe | Apatinib + GTb | 3 | PR | (7.4) |
| Extraskeletal osteosarcoma | Apatinib alone | 1 | SD | 6.6 |
| Mucinous type liposarcoma | Apatinib alone | 1 | PD | 1.0 |
aPR partial response, SD stable disease according to RECIST 1.1
bGT chemo-protocol combined with gemcitabine 1000 mg/m2 d1,8 and docetaxel 75 mg/m2 d8
cMPNST malignant peripheral nerve sheath tumor
dUPS undifferentiated pleomorphic sarcoma
eASPS alveolar soft part sarcoma